Table 2 Distribution of clinicopathological characteristics in patients with high and low CD3 expression in both the training and test groups.

From: Preoperative MRI-based radiomics analysis of intra- and peritumoral regions for predicting CD3 expression in early cervical cancer

Characteristics

Training group (n = 140)

Test group (n = 62)

High

Low

p

High

Low

p

Age, years

55.31 ± 9.898

51.582 ± 10.563

0.053

53.976 ± 10.951

52.381 ± 11.061

0.591

Clinical complaint

  

0.409

  

0.885

Postcoital bleeding

37 (88.1%)

78 (79.6%)

 

24 (58.5%)

13 (61.9%)

 

Incidental finding

3 (7.1%)

15 (15.3%)

 

3 (7.3%)

2 (9.5%)

 

Increased secretion

2 (4.8%)

5 (5.1%)

 

14 (34.1%)

6 (28.6%)

 

Pregnancy

  

0.427

  

0.527

None

0 (0.0%)

1 (1.0%)

 

0 (0.0%)

0 (0.0%)

 

Single

1 (2.4%)

7 (7.1%)

 

4 (9.8%)

4 (19.0%)

 

Several

41 (97.6%)

90 (91.8%)

 

37 (90.2%)

17 (81.0%)

 

Parturition

  

0.362

  

0.907

None

0 (0.0%)

4 (4.1%)

 

0 (0.0%)

0 (0.0%)

 

Single

12 (28.6%)

31 (31.6%)

 

15 (36.6%)

8 (38.1%)

 

Several

30 (71.4%)

63 (64.3%)

 

26 (63.4%)

13 (61.9%)

 

HPV

  

0.103

  

0.35

Negative

15 (35.7%)

22 (22.4%)

 

4 (9.8%)

0 (0.0%)

 

Positive

27 (64.3%)

76 (77.6%)

 

37 (90.2%)

21 (100.0%)

 

SCC, ng/mL

1.82 (1.078–4.643)

1.12 (0.718–3.132)

0.015*

1.37 (0.92–3.32)

1.68 (0.89–3.8)

0.994

CA125, u/mL

14.45 (9.808–16.875)

14.45 (9.123–17.3)

0.553

13.6 (8.67–17.76)

17.61 (10.22–18.86)

0.252

RBC, 1012/L

4.135 (3.762–4.433)

4.115 (3.857–4.365)

0.815

4.07 (3.89–4.4)

4.36 (3.96–4.51)

0.096

PLT, 109/L

229 (185.25–271.5)

239.5 (181–283)

0.592

191 (150–245)

258 (211–313)

0.001*

Neutrophil, 109/L

3.15 (2.322–4.228)

2.915 (2.292–3.628)

0.329

2.92 (2.34–3.91)

3.81 (2.9–4.77)

0.071

Lymphocyte, 109/L

1.845 ± 0.497

1.784 ± 0.575

0.552

1.711 ± 0.705

1.835 ± 0.513

0.249

Hemoglobin, g/L

125.5 (118.5–132.75)

122.5 (114–130)

0.192

122 (113–129)

122 (115–135)

0.557

NLR

1.72 (1.075–2.513)

1.614 (1.324–2.286)

0.955

2.057 (1.535–2.482)

2.023 (1.593–2.41)

0.701

PLR

121.254 (94.379–160.55)

139.069 (104.851–174.722)

0.214

127.966 (92.271–167.361)

151.497 (113.194–173.46)

0.13

Pre FIGO stage

  

0.338

  

0.001*

IA

2 (3.6%)

0 (0.0%)

 

0 (0.0%)

0 (0.0%)

 

IB

22 (39.3%)

81 (96.4%)

 

10 (34.5%)

31 (93.9%)

 

IIA

32 (57.1%)

3 (3.6%)

 

19 (65.5%)

2 (6.1%)

 

Tumor longest diameter, mm

32.008 ± 8.888

25.931 ± 10.971

0.002*

24.96 ± 10.827

22.617 ± 5.507

0.047*

Stromal ring

  

0.001*

  

0.424

Continuous

14 (33.3%)

62 (63.3%)

 

20 (48.8%)

8 (38.1%)

 

Interrupt

28 (66.7%)

36 (36.7%)

 

21 (51.2%)

13 (61.9%)

 

meanADC, mm2/s

0.092 (0.084–0.1)

0.094 (0.067–0.129)

0.588

0.09 (0.078–0.105)

0.096 (0.087–0.099)

0.552

medADC, mm2/s

0.089 (0.082–0.099)

0.092 (0.066–0.125)

0.995

0.086 (0.077–0.101)

0.09 (0.084–0.098)

0.48

  1. LVSI, lymph-vascular space invasion; RBC, red blood cell; PLT, platelet; NLR, neutrophil/lymphocyte; PLR, platelet/lymphocyte; HPV, human papilloma virus; SCC, squamous cell carcinoma antigen; CA125, cancer antigen 125; FIGO, 2018, International Federation of Gynecology and Obstetrics; ADC, apparent diffusion coefficients; medADC, median ADC; meanADC, mean ADC; SD, standard deviation.
  2. p < 0.05. *represents a statistically significant difference.
Back to article page